DE1914822C3 - External agent to prevent irritation, inflammation and sensitization - Google Patents

External agent to prevent irritation, inflammation and sensitization

Info

Publication number
DE1914822C3
DE1914822C3 DE19691914822 DE1914822A DE1914822C3 DE 1914822 C3 DE1914822 C3 DE 1914822C3 DE 19691914822 DE19691914822 DE 19691914822 DE 1914822 A DE1914822 A DE 1914822A DE 1914822 C3 DE1914822 C3 DE 1914822C3
Authority
DE
Germany
Prior art keywords
sensitization
inflammation
uric acid
external agent
irritation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
DE19691914822
Other languages
German (de)
Other versions
DE1914822A1 (en
DE1914822B2 (en
Inventor
Bernhard Dr. Zuerich Joos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to DE19691914822 priority Critical patent/DE1914822C3/en
Priority to CH466769A priority patent/CH523069A/en
Priority to CA047,530A priority patent/CA944695A/en
Priority to FR6910286A priority patent/FR2035798A1/en
Priority to IT1521069A priority patent/IT1001456B/en
Publication of DE1914822A1 publication Critical patent/DE1914822A1/en
Publication of DE1914822B2 publication Critical patent/DE1914822B2/en
Application granted granted Critical
Publication of DE1914822C3 publication Critical patent/DE1914822C3/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/005—Preparations for sensitive skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)

Description

Die Anmeldung betrifft den im Anspruch genau bezeichneten Gegenstand.The application relates to the subject matter specified in the claim.

Im deutschen Patent 17 67165 ist ein äußerlich anwendbares Mittel zur Verhütung von Reizungen, Entzündungen und Sensibilisierungen beschrieben, welches durch den Gehalt an mindestens einem der Xanthinderivate Koffein, Theophyllin oder Theobromin in einer Konzentration von 0,1 bis 10Gew.% gekennzeichnet ist.In German patent 17 67165 is an external applicable agent to prevent irritation, inflammation and sensitization is described, which by the content of at least one of the xanthine derivatives caffeine, theophylline or theobromine in a concentration of 0.1 to 10% by weight is.

Es wurde nun gefunden, daß man anstelle von oder zusammen mit einem Xanthin auch ein anderes Purin-Derivat, nämlich Harnsäure, vorteilhaft einsetzen kann. Wie beim Xanthin, hat sich in der Praxis gezeigt, daß entzündliche Reizungen, die bei der Verwendung von Aldehyden, gedeckten Aldehyden. Methylolverbindungen oder deren Derivaten auftreten, auch bei Zugabe von Harnsäure stark zurückgehen und aufgehoben werden können. Versuche, die sich über längere Zeiträume erstrecken, führten zu der Erkenntnis, daß bereits relativ geringe Mengen an Purin-Dcrivaten die unangenehmen Nebenwirkungen der obengenannten Verbindungen aufheben können, wobei sich diese Wirkung außer auf die Haut auch auf andere Partien, wie beispielsweise die Schleimhaut, bezieht.It has now been found that instead of or together with one xanthine, another Purine derivative, namely uric acid, can be used advantageously. As with xanthine, it has been shown in practice that inflammatory irritation caused by the use of aldehydes, muted aldehydes. Methylol compounds or their derivatives occur, even when uric acid is added, they decrease sharply and are abolished can be. Tests that extend over longer periods of time have led to the finding that even relatively small amounts of purine derivatives have the unpleasant side effects of the above Compounds can cancel, this effect not only on the skin but also on other areas, such as the mucous membrane relates.

Das erfindungsgemäße Mittel kann ebenso wie das Mittel des deutschen Patentes 17 67 165 zusätzlich Harnstoff oder Thioharnstoff und deren Derivate, Aminosäuren, wie Glykokoll oder p-Aminobenzoesäure, oder schwefelige Säure und ihre Salze enthalten.The agent according to the invention can, like the agent of German patent 17 67 165, in addition Urea or thiourea and their derivatives, amino acids, such as glycocolla or p-aminobenzoic acid, or contain sulphurous acid and its salts.

Die folgenden Beispiele erläutern die Erfindung.The following examples illustrate the invention.

Beispiel 1example 1

Eine 7%-ige Dimethylolthioharnstofflösung, enthaltend 25% Alkohol und 0,1% Formaldehyd, wurde mit 0,5% Harnsäure versetzt und auf die Haut gebracht. Mit Zusatz erfolgt keine Reizung, die jedoch ohne Zusatz is auftrat.A 7% dimethylolthiourea solution containing 25% alcohol and 0.1% formaldehyde was with 0.5% uric acid added and applied to the skin. With There is no additional irritation, which, however, occurred without the addition.

Beispiel 2Example 2

Eine 7%-ige Dimethylolharnstofflösung, enthaltend 10% Alkohol und 0,6% Formaldehyd, wurde mit 0,5% 2ü Harnsäure und 0,5% Coffein versetzt und verursachte bei Aufbringen auf die Haut keine Reizung, was jedoch der Fall war. wenn das Coffein und die Harnsäure nicht anwesend waren.A 7% dimethylolurea solution containing 10% alcohol and 0.6% formaldehyde was 0.5% 2ü uric acid and 0.5% caffeine added and caused no irritation when applied to the skin, but that was the case. if the caffeine and uric acid don't were present.

,. Bei s ρ i e I 3,. At s ρ i e I 3

Eine 5%-ige Dimethylolthioharnstofflösung, enthaltend 20% Alkohol und 0,5% Formaldehyd, wurde mit 0,5% Harnsäure und 3% Glykokoll versetzt. Bei Einwirkung der Lösung auf die Haut trat keine Reizung so ein, wenn das Purin zugegen war. Sie trat jedoch ein, wenn kein Purin enthalten war.A 5% dimethylolthiourea solution containing 20% alcohol and 0.5% formaldehyde was with 0.5% uric acid and 3% glycocolla added. No irritation occurred when the solution came into contact with the skin so when the purine was present. However, she entered when no purine was included.

Beispiel 4Example 4

Eine 14%-ige Dimethylolaethylenthioharnsiofflösung, enthaltend 25% Alkohol und 0,25% Formaldehyd, wurde mit 0,5% Harnsäure und 1% Natriumhydrosulfit versetzt. Auch hier stellte sich bei Einwirkung der Lösung auf die Haut keine Reizung ein, wenn das Purin zugegen war, die jedoch auftrat, wenn keine HarnsäureA 14% dimethylolaethylene thiourine solution, containing 25% alcohol and 0.25% formaldehyde, was made with 0.5% uric acid and 1% sodium hydrosulfite offset. Here, too, there was no irritation when the solution acted on the skin, if the purine was present, but it occurred when there was no uric acid

•»ο vorhanden war.• »ο was present.

Claims (1)

Patentanspruch:Claim: Äußerlich anwendbare Lösung mit einem Gehalt an Aldehyden, Methylolverbindungen oder deren Derivaten, wobei die Lösung zusätzlich mindestens eine der zur Puringruppe gehörenden Xanthinverbindungen Koffein, Theophyllin, Theobromin oder Theophyllin-Ethylendiamin in einer Konzentration von 0,1 bis 10 Gewichtsprozent enthält, nach Patent 17 67 165, dadurch gekennzeichnet, daß die Xanthinverbindungen mindestens teilweise durch das Purinderivat Harnsäure ersetzt sind.Externally applicable solution with a content of aldehydes, methylol compounds or their Derivatives, the solution additionally having at least one of the xanthine compounds belonging to the purine group Caffeine, theophylline, theobromine or theophylline-ethylenediamine in one concentration Contains from 0.1 to 10 percent by weight, according to Patent 17 67 165, characterized in that the xanthine compounds are at least partially replaced by the purine derivative uric acid.
DE19691914822 1968-04-06 1969-03-22 External agent to prevent irritation, inflammation and sensitization Expired DE1914822C3 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
DE19691914822 DE1914822C3 (en) 1969-03-22 1969-03-22 External agent to prevent irritation, inflammation and sensitization
CH466769A CH523069A (en) 1968-04-06 1969-03-27 Cosmetic skin treatment agent
CA047,530A CA944695A (en) 1968-04-06 1969-04-01 Externally applicable composition for protecting the skin against substances that have a primarily or secondarily toxic or sensitising effect
FR6910286A FR2035798A1 (en) 1968-04-06 1969-04-03 Compns contng xanthines for external use in treatment
IT1521069A IT1001456B (en) 1968-04-06 1969-04-05 MEDIUM TO BE USED OUTSIDE FOR THE PROTECTION OF THE SKIN WITH MANY SUBSTANCES HAVING TOXIC OR PRIMARY OR PURE SECONDARY SENSITIZING ACTION

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19691914822 DE1914822C3 (en) 1969-03-22 1969-03-22 External agent to prevent irritation, inflammation and sensitization

Publications (3)

Publication Number Publication Date
DE1914822A1 DE1914822A1 (en) 1970-10-01
DE1914822B2 DE1914822B2 (en) 1979-10-25
DE1914822C3 true DE1914822C3 (en) 1980-07-17

Family

ID=5729082

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19691914822 Expired DE1914822C3 (en) 1968-04-06 1969-03-22 External agent to prevent irritation, inflammation and sensitization

Country Status (1)

Country Link
DE (1) DE1914822C3 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10123966B2 (en) 2013-05-16 2018-11-13 The Procter And Gamble Company Hair thickening compositions and methods of use

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10123966B2 (en) 2013-05-16 2018-11-13 The Procter And Gamble Company Hair thickening compositions and methods of use

Also Published As

Publication number Publication date
DE1914822A1 (en) 1970-10-01
DE1914822B2 (en) 1979-10-25

Similar Documents

Publication Publication Date Title
DE1670827C3 (en) 4- (2'-nitrophenyl) -2,6-dimethyl-3,5-dicarbmethoxy-1,4-dihydropyridine
DE1492173A1 (en) Method of preserving blood
DE1914822C3 (en) External agent to prevent irritation, inflammation and sensitization
DE1244762B (en) Stabilization of urea solutions
DE1282855B (en) Cosmetic light protection agent
DE1767165B2 (en) EXTERIORLY APPLICABLE SOLUTION WITH A CONTENT OF ALDEHYDE, METHYLOL COMPOUNDS OR THEIR DERIVATIVES
DE1902148A1 (en) Color-stabilized mixture of substances containing vitamin C.
DE537451C (en) Process for the preparation of water-soluble nitrogen-containing condensation products
AT205670B (en)
DE639673C (en) Process for the production of easily soluble double compounds from chlorophyllin and xanthine bases
DE683866C (en) Process for the production of durable aqueous solutions of p-aminobenzenesulfonamide
DE762284C (en) Process for increasing the water solubility of dimethylxanthines and their compounds
DE703556C (en) Sliding fastening of textile fabrics
DE580710C (en) Solid, durable hydrogen peroxide preparations
DE1916254C3 (en) Process for preventing precipitation or for redissolving existing cloudiness in aqueous solutions of aminocarboxylic acids
DE2122293B2 (en) Depilatories
DE675674C (en) Process for the production of solid molecular compounds consisting of the complex mercury compound of salicylallylamido-acetic acid sodium and alkyl purines
CH637826A5 (en) Intravenous, aqueous SULFONAMIDLOESUNG AND METHOD FOR PRODUCING.
DE632131C (en) Process for converting vitamin B into a fat-soluble, easily split form
DE951757C (en) Method for stabilizing ergot alkaloids
DE874898C (en) Process for stabilizing textile finishing agents
DE748005C (en) Process for the production of readily water-soluble compounds of theophylline or caffeine
DE1154899B (en) Process for increasing the solubility of purines and purine derivatives
AT99940B (en) Process for converting water-insoluble or sparingly soluble drugs into drip and injectable form.
DE1151096B (en) Process for the production of stable, concentrated aqueous solutions of oxyalkylated theophylline or oxyalkylated theobromine compounds

Legal Events

Date Code Title Description
C3 Grant after two publication steps (3rd publication)